Tissue engineering constructs that merely resemble an organ are no longer enough, according to an editorial introducing a new Research Topic in Frontiers in Bioengineering and Biotechnology. The collection, edited by Yifan Wang and Zheng Wang of Chinese PLA General Hospital, gathers eight contributions that connect material design, additive manufacturing, and validation so that a construct’s intended function can be measured and reproduced rather than assumed.
The editorial argues that functional tissue engineering asks more of a construct than anatomical resemblance: it must serve a defined biological purpose and retain that capacity after fabrication. Responsive materials can couple local cues to therapeutic release or cell regulation, while additive manufacturing can organize cells and matrices in controlled architectures. The challenge, the editors write, is linking these steps so that performance claims survive scrutiny.
Two review articles address how computational tools can guide material selection. Zhang and colleagues survey artificial intelligence across hydrogel bioink design, printability prediction, process monitoring, and construct validation, distinguishing established applications from prospective closed-loop bioprinting and emphasizing external validation and biological endpoints. Ding and colleagues extend the design problem to functional peptides, showing how foundation models can prioritize antimicrobial, targeting, and cell-instructive candidates, while cautioning that peptide activity must survive immobilization, crosslinking, and printing. Both reviews frame AI as a tool for choosing testable materials, not as evidence of construct performance.
Traceability of evidence after candidates enter biological studies is the focus of a separate contribution. Li and colleagues assembled SenescenceBioKG, a knowledge graph built from 283 full-text studies linking material features, cellular targets, mechanisms, and regenerative outcomes within the same reports. Their analysis identifies recurring responsive designs but also sparse organoid, large-animal, and clinical evidence, making validation gaps visible without treating co-occurrence as proof of causation.
Bone cancer illustrates the difficulty of combining therapeutic and regenerative functions in one implant. Xu and colleagues review bifunctional scaffolds designed to suppress osteosarcoma while supporting bone regeneration, including stimuli-responsive release and patient-specific printing. In a complementary opinion piece, Li and colleagues propose AI-guided photoresponsive nanoplatforms that could adjust treatment intensity as tumor and repair needs change. The editors stress that this proposal is a conceptual direction whose feedback control still requires experimental demonstration, and that both articles expose the need to test cancer control and bone repair together over relevant timescales.
A direct experimental example comes from Tian and colleagues, who functionalized an electrospun scaffold with polydopamine-bound curcumin for infected wounds. Their in vitro assays and an infected rat wound model reported antibacterial, antioxidant, immunomodulatory, and pro-angiogenic effects alongside improved healing. The editors note that the study shows how several intended functions can be evaluated in one disease-relevant construct, although broader reproducibility and clinical performance remain open questions.
Disease context also determines which evidence matters. Wang and colleagues mapped 596 glaucoma-related biomaterial publications and found an uneven shift from drug delivery toward smart materials, additive manufacturing, and functional tissue models. Their findings point to a need for disease-specific endpoints rather than assuming that a sophisticated material confers functional benefit. In general surgery, Lou and colleagues reviewed responsive hydrogels, bioinks, and patient-specific scaffolds against practical failure modes such as leakage, infection, and impaired tissue integration, proposing a GS0–GS5 hierarchy that connects material tests to the conditions of surgical use.
The editorial closes with a checklist-like requirement that runs across all eight contributions: an explicit chain from a material or computational choice to a manufacturable construct and then to a relevant biological outcome. A responsive signal needs a defined threshold and duration; a printable formulation needs documented process conditions and quality controls; a predicted benefit needs prospective testing in the intended tissue setting.
By placing functional validation and reproducibility alongside material novelty, the Research Topic aims to make next-generation smart, additively manufactured tissue constructs easier to compare and more credible as candidates for translation.
Subject of Research: An editorial introducing a Research Topic on smart materials and additive manufacturing for functional tissue engineering, spanning AI-guided design, evidence mapping, and experimental scaffolds.
Article Title: Editorial: Smart materials and additive manufacturing for functional tissue engineering
Article References: Wang, Y., & Wang, Z. (2026). Editorial: Smart materials and additive manufacturing for functional tissue engineering. Frontiers in Bioengineering and Biotechnology, 14, Article 2019823. https://doi.org/10.3389/fbioe.2026.2019823
Image Credits: AI Generated
DOI: 10.3389/fbioe.2026.2019823
Keywords: tissue engineering, additive manufacturing, smart biomaterials, bioinks, artificial intelligence, functional validation, bone regeneration, osteosarcoma, electrospun scaffolds, curcumin, glaucoma, responsive hydrogels
News Source: Denise Maddox. (October 29, 2026). Smart Materials and 3D Printing Move Tissue Engineering Toward Functional Validation. Scienmag.
